2.50
Hdl Handle:
http://hdl.handle.net/10541/59013
Title:
Development of antiangiogenic agents for ovarian cancer.
Authors:
Collinson, Fiona J; Hall, Geoff D; Perren, Timothy J; Jayson, Gordon C ( 0000-0002-8515-8944 )
Abstract:
Epithelial ovarian cancer (EOC) remains a major source of cancer morbidity and mortality, despite advances in surgical and chemotherapeutic management. The molecular pathways that control angiogenesis have been demonstrated to be key to the pathogenesis of EOC, and have been shown to have prognostic significance. Increased understanding of the pathways and molecules involved in angiogenesis has allowed the identification of a number of targets for antiangiogenic therapies and the development of a variety of antiangiogenic drugs. There is now significant preclinical evidence, and a growing body of clinical data, demonstrating promising results with antiangiogenic drugs in the treatment of EOC. Single-agent VEGF inhibitor response rates in pretreated patients of between 15 and 20% have been reported, with much higher response rates when used in combination with chemotherapeutic agents. These benefits, however, must be balanced with the toxicities associated with these drugs, particularly the more serious ones, such as gastrointestinal perforation. The results of ongoing and future randomized clinical trials will confirm if, and how, antiangiogenic therapies should be integrated into the routine management of EOC. However, critical issues, such as the relative importance of combination remission induction regimens and maintenance therapy, remain poorly defined.
Affiliation:
Department of Medical Oncology, St James' University Hospital, Leeds, UK. fjcollinson@doctors.org.uk
Citation:
Development of antiangiogenic agents for ovarian cancer. 2008, 8 (1):21-32 Expert Rev Anticancer Ther
Journal:
Expert Review of Anticancer Therapy
Issue Date:
Jan-2008
URI:
http://hdl.handle.net/10541/59013
DOI:
10.1586/14737140.8.1.21
PubMed ID:
18095880
Type:
Article
Language:
en
ISSN:
1744-8328
Appears in Collections:
All Christie Publications ; Medical Oncology

Full metadata record

DC FieldValue Language
dc.contributor.authorCollinson, Fiona J-
dc.contributor.authorHall, Geoff D-
dc.contributor.authorPerren, Timothy J-
dc.contributor.authorJayson, Gordon C-
dc.date.accessioned2009-04-02T15:49:29Z-
dc.date.available2009-04-02T15:49:29Z-
dc.date.issued2008-01-
dc.identifier.citationDevelopment of antiangiogenic agents for ovarian cancer. 2008, 8 (1):21-32 Expert Rev Anticancer Theren
dc.identifier.issn1744-8328-
dc.identifier.pmid18095880-
dc.identifier.doi10.1586/14737140.8.1.21-
dc.identifier.urihttp://hdl.handle.net/10541/59013-
dc.description.abstractEpithelial ovarian cancer (EOC) remains a major source of cancer morbidity and mortality, despite advances in surgical and chemotherapeutic management. The molecular pathways that control angiogenesis have been demonstrated to be key to the pathogenesis of EOC, and have been shown to have prognostic significance. Increased understanding of the pathways and molecules involved in angiogenesis has allowed the identification of a number of targets for antiangiogenic therapies and the development of a variety of antiangiogenic drugs. There is now significant preclinical evidence, and a growing body of clinical data, demonstrating promising results with antiangiogenic drugs in the treatment of EOC. Single-agent VEGF inhibitor response rates in pretreated patients of between 15 and 20% have been reported, with much higher response rates when used in combination with chemotherapeutic agents. These benefits, however, must be balanced with the toxicities associated with these drugs, particularly the more serious ones, such as gastrointestinal perforation. The results of ongoing and future randomized clinical trials will confirm if, and how, antiangiogenic therapies should be integrated into the routine management of EOC. However, critical issues, such as the relative importance of combination remission induction regimens and maintenance therapy, remain poorly defined.en
dc.language.isoenen
dc.subjectOvarian Canceren
dc.subjectEpithelial Ovarian Canceren
dc.subject.meshAngiogenesis Inhibitors-
dc.subject.meshFemale-
dc.subject.meshHumans-
dc.subject.meshNeovascularization, Pathologic-
dc.subject.meshOvarian Neoplasms-
dc.titleDevelopment of antiangiogenic agents for ovarian cancer.en
dc.typeArticleen
dc.contributor.departmentDepartment of Medical Oncology, St James' University Hospital, Leeds, UK. fjcollinson@doctors.org.uken
dc.identifier.journalExpert Review of Anticancer Therapyen

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.